AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Context Therapeutics Inc. (CNTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.79

-0.05 (-5.95%)

At close: Feb 20, 2025, 3:59 PM

0.79

-0.32%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	0.78
Market Cap	59.44M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.88
PE Ratio (ttm)	-0.9
Forward PE	n/a
Analyst	Buy

Ask	0.8
Volume	517,149
Avg. Volume (20D)	508,069
Open	0.85
Previous Close	0.84
Day's Range	0.77 - 0.83
52-Week Range	0.77 - 2.75
Beta	undefined

About CNTX

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also dev...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 20, 2021

Employees 5

Stock Exchange NASDAQ

Ticker Symbol CNTX

Website https://www.contexttherapeutics.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for CNTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 657.10% from the latest price.

Buy 80.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

9 months ago

+28.68%

Context Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

News

5 months ago · zacks.com

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

7 months ago · seekingalpha.com

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipe...

8 months ago · investorplace.com

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more.

9 months ago · investorplace.com

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.

9 months ago · zacks.com

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago · proactiveinvestors.com

Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024

Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, toward a ...

1 year ago · proactiveinvestors.com

Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody...

1 year ago · proactiveinvestors.com

Context Therapeutic says it has enough cash to fund operation into late 2024

Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has sufficient cash and cash equivalents to continue fundin...

1 year ago · zacks.com

Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

1 year ago · proactiveinvestors.com

Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's cash runway into late 2024. CTIM-76, a Claudin 6 (C...

Load More News